Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

198
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
198
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

452
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
452
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

247
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
247
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

653
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
653
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

863
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
863

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Theta band activity during event-file retrieval is influenced by stimulus salience in the preceding action episode.

Cortex; a journal devoted to the study of the nervous system and behavior·2026
Same author

Bioenergetic dysregulation in the basal ganglia and cerebellum of patients with premanifest and manifest Huntington's disease.

Neurobiology of disease·2026
Same author

Altered neurodevelopmental trajectories of brain structure in Tourette syndrome and Chronic Tic Disorders.

medRxiv : the preprint server for health sciences·2026
Same author

Distinct Brain Drivers and Shared Cerebello-Cortical Input in ADCY5 and SGCE Hyperkinetic Movements.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Metabolic and Volumetric Alterations in the Basal Ganglia and the Cerebellum in Dopa-Responsive Dystonia in Symptomatic and Asymptomatic GCH1 Mutation Carriers.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

[The unmet need for psychiatric and psychotherapeutic care for refugees - A local pilot survey in Lübeck].

Psychiatrische Praxis·2026

相关实验视频

Updated: May 31, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K

在对多巴反应性 dystonia 中的功能运动障碍.

Feline Hamami1, Jannik Prasuhn2, Leon-Claas van Well3

  • 1Institute of Systems Motor Science, University Medical Center Schleswig-Holstein, University of Lübeck, Lübeck, Germany; Center for Brain, Behavior, and Metabolism, University of Lübeck, Lübeck, Germany.

Parkinsonism & related disorders
|January 23, 2025
PubMed
概括

功能神经运动障碍经常与多巴反应性 dystonia 一起发生,显著增加患者的残疾. 早期诊断对于适当的治疗至关重要,避免无效的L-Dopa增加和指导物理治疗.

关键词:
在DRD中,DRD是DRD.对多巴反应性 dystonia 的反应.功能性运动障碍 功能性运动障碍功能神经系统疾病 功能神经系统疾病在 GCH1 中.

更多相关视频

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.3K

相关实验视频

Last Updated: May 31, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.3K

科学领域:

  • 神经学 神经学
  • 运动障碍 运动障碍
  • 神经科学是一个神经科学.

背景情况:

  • 功能神经运动障碍 (FNMDs) 是普遍存在的,使人衰弱的.
  • 了解FNMD和其他运动障碍之间的重叠是有限的.

研究的目的:

  • 确定GCH1阳性多巴反应性 dystonia (DRD) 患者的 FNMDs 的频率和特征.

主要方法:

  • 一组21名DRD患者接受了详细的运动检查.
  • 患者填写了自我问卷,评估非运动症状.

主要成果:

  • 33%的DRD患者患有并发性FNMD,包括步态和平衡障碍,以及虚弱.
  • 这些功能性症状主导了临床情况,导致严重的残疾和固定.
  • 功能性症状在DRD发病多年后出现,L-Dopa无反应,导致不必要的治疗.

结论:

  • 在DRD患者中,FNMDs很常见,严重影响残疾.
  • 准确的诊断至关重要,以避免不适当的L-Dopa升级,并指导量身定制的物理治疗.
  • 治疗应整合专注于自动运动的物理治疗,以及精神教育和心理治疗.